Introduction
Despite potent antiretroviral therapy (ART) HIV-1-infected (HIV þ ) individuals have an approximately twofold increased risk of atherosclerotic cardiovascular disease (CVD), but the mechanisms are unclear [1] . High-density lipoprotein (HDL) levels are a powerful independent negative predictor of CVD; however, HDL structure and function rather than absolute level may more accurately predict atherosclerosis [1] . HIV þ ART-treated individuals have a higher prevalence of dyslipidemia, low HDL levels [1] , impaired lipoprotein metabolism, and increased HDL lipid hydroperoxide content and redox activity (HDLox) [2] that are associated with CVD in some, but not all studies [3] [4] [5] . In HIV-uninfected (HIV À ) persons, abnormal HDL function strongly correlates with CVD [6] , but there is limited evidence in HIV infection.
Cell-based assays such as cholesterol efflux assays [7] have been used to determine HDL function, but have numerous drawbacks including heterogeneity with regards to cells used, reported readout, and standardization [3, 4] . Cell-free assays may give more robust measures of HDL function compared with cell-based assays [4] . We have developed a novel cell-free fluorometric method that measures HDL-associated lipid peroxidation (HDL ox ) and hence reduction of HDL antioxidant function [3, 4] . In HIV þ ART-treated participants with low CVD risk, the readout from our assay correlated with coronary artery calcium score, carotid intima media thickness (surrogate measures of subclinical atherosclerosis) and macrophage activation [3] [4] [5] . Furthermore, impaired HDL antioxidant function (as measured by higher HDL ox ) was associated with impaired HDL remodeling [8] (a CVD-relevant measure of HDL function [9] ) using a cell-free assay that measures the ability of HDL to release apolipoprotein A-I (ApoA-I) [HDL-ApoA-I exchange (HAE)] [9, 10] . Thus, use of two independent cell-free assays of HDL activity may more accurately reflect HDL dysfunction in treated HIV þ persons.
Monocytes play a central role in the development of atherosclerosis, and HIV-related chronic monocyte activation may contribute to increased CVD, but the mechanisms are unknown. Using an established in vitro model of early atherosclerotic events, we have shown that monocytes from HIV þ individuals have a greater potential to develop into lipid-laden foam cells (which are associated with plaque progression) following transendothelial migration than monocytes from age-matched HIVÀ controls [11] . Furthermore, we found that serum factors from ART-treated HIV þ individuals further promote monocyte-derived foam cell formation (MDFCF) [11] . We have shown that dysfunctional HDL persists in virologically suppressed HIV þ individuals [3, 4] on potent ART and may be the circulating factor that directly promotes MDFCF, a key event in HIV-related CVD. This research question can be reliably studied in a large prospective study of HIV-1 infected persons on chronic ART and well matched uninfected controls, where complex effects of confounders on MDFCF need to be dissected. Given the above complexities, known limitations of all HDL function assays, and lack of any preliminary data that support the role of dysfunctional HDL in promoting MDFCF, it would be difficult to design such as prospective study. Thus, to address this question, we conducted an exploratory study using a subset of samples from an established cohort of HIV þ individuals on potent ART with low CVD risk specifically selected to be matched for relevant factors. We isolated native HDL from a homogeneous group of HIV þ persons and incubated it directly with monocytes from healthy participants to dissect effects of HIV(þ) HDL, independent to the documented effect of HIV on MDFCF [11] in an established ex-vivo model of early atherosclerotic events.
Methods

Study design and participants
The work utilized samples from the Center for Clinical AIDS Research and Education HDL function study; a cross-sectional study investigating impaired HDL function among viremic and virologically suppressed HIV þ men on stable ART [8] . Sociodemographic and clinical characteristics, and measures of HDL function (HDL ox , HAE %) have been described [8] . To avoid confounding effects from sex [12] , inflammation (other than HIV), traditional CVD risk factors and ART on atherogenesis, we selected HIV þ persons with the following inclusion criteria: men, no known inflammatory comorbidities other than HIV, no known CVD or risk factors for CVD (e.g., metabolic syndrome, diabetes, dyslipidemia, use of lipid lowering medication, hypertension, family history of CVD, Framingham Risk Score !6%), on stable and identical ART more than 6 months prior to visit, and with dysfunctional HDL as defined by two independent cell-free assays of HDL function. In the setting of our exploratory study, we selected 10 HIV-1-infected persons from this group who had the highest HDLox and lowest HAE to explore the question whether dysfunctional HDL in the setting of low CVD risk directly upregulates MDFCF. Five healthy men matched by age and race to the HIV þ group were also included. All individuals enrolled in the study provided written informed consent and the study was approved by the local Institutional Review Boards.
Lipoprotein preparation, oxidation, and determination of high-density lipoprotein function HDL was purchased (EMD Millipore, Billerica, Massachusetts, USA) or isolated from plasma using ultracentrifugation and lipoproteins were oxidized in vitro as previously [9, 10] . HDL ox was quantified using a validated fluorometric assay that measures HDL lipid peroxidation based on the oxidation of the fluorochrome Amplex Red (Thermo Fisher Scientific, Waltham, Massachusetts) [9, 10] . HAE assays were performed as previously described [8] . Different aliquots of identical HDL were used for the HDL ox , HAE, and the foam cell assays.
In-vitro model of monocyte migration and foam cell formation
The in-vitro MDFCF assay was performed using monocytes purified via negative selection (Miltenyi Biotec, Cologne, Germany) from freshly isolated peripheral blood mononuclear cells from healthy donors [11] . Monocytes were preincubated with 20 mg/ml donor or commercial HDL [unmodified or oxidized with copper(II) sulfate (CuSO 4 ) or 13(S)-hydroperoxy-9Z, 11E-octadecadienoic acid (13(S)-HPODE)] in serum-free media for 1 hr. Monocytes were then added to tumor necrosis factor-activated human umbilical vein endothelial cells monolayers on type I fibrous collagen gels to transmigrate and form foam cells as previously described (Supplemental Figure 1 , http://links.lww. com/QAD/B159). Lipids were maintained in the media throughout the experiment.
Detailed methods are described in the supplemental material, http://links.lww.com/QAD/B159
Results
Baseline characteristics Baseline characteristics of the study participants are shown in Table 1 . HIV þ participants (median age: 42 years; n ¼ 10) had suppressed viremia (<50 copies/ml) and the group overall had a low CVD risk (Framingham Risk Score <6%). All HIV þ persons were on stable ART more than 6 months prior to visit with efavirenz/emtricitabine/ tenofovir disoproxil fumarate. HIV þ and control participants had comparable lipid profiles, Framingham Risk Score, and rates of cytomegalovirus seropositivity.
Dysfunctional high-density lipoprotein present in virologically suppressed, antiretroviral therapy-treated HIV-1 infection directly increases monocyte-derived foam cell formation To investigate whether HDL dysfunction (as indicated by cell-free assays) was associated with proatherogenic effects, we used isolated HDL, assessed to be dysfunctional, from ART-treated HIV þ individuals [(HIV(þ) HDL, n ¼ 10)] and compared their influence on MDFCF in vitro to HDL isolated from healthy controls (HIV(À)HDL, n ¼ 5). The decreased function of the isolated HDL assessed using two independent assays is presented in Fig. 1 . Median HDL ox of HIV þ persons was $50% higher compared with uninfected participants (Fig. 1a , P < 0.001). ART-treated HIV þ study participants had $35% lower median %HAE compared with HIVÀ participants (P < 0.001, Fig. 1b, Table 1 ).
Next, isolated donor HDL were preincubated with monocytes from HIV À individuals prior to (and maintained in culture throughout) analysis in our invitro foam cell model (Supplemental Figure 1 , http:// links.lww.com/QAD/B159). When media-containing dysfunctional HIV(þ)HDL was added to tumor necrosis factor-activated human umbilical vein endothelial cell, a significantly increased proportion of monocytes differentiated into foam cells as compared with the same monocytes exposed to media-containing HDL from HIV À persons (median foam cells 33 vs. 26.2%, respectively, P ¼ 0.015, Fig. 1c ; from n ¼ 3 replicate experiments using monocytes from three individual HIV À donors).
In-vitro oxidized high-density lipoprotein directly increases monocyte-derived foam cell formation Given that oxidation of HDL leads to abnormal HDL function, we next compared the magnitude of the proatherogenic effects of HIV(þ)HDL with chemically derived HDL ox . In-vitro oxidation of lipoproteins using CuSO 4 , although widely used, has uncertain physiological relevance as this type of oxidation does not occur in vivo. Therefore, we also used 13(S)-HPODE, a potent invivo-generated lipid that renders HDL dysfunctional [8] as a comparator. Both forms of HDL ox were associated with a significant increase in foam cell formation by healthy monocytes following transendothelial migration HDL lipid peroxide content (HDL ox ) was measured by Amplex Red assay of lipid peroxidation and was normalized by total HDL levels and readout of pooled HDL control as described in methods and previously. HAE is expressed as a percentage of maximum response as measured by EPR spectroscopy and as described in methods and previously. Monocyte-derived foam cell formation following incubation with HDL isolated from the above individuals (c, each HDL sample tested separately) or commercially produced HDL oxidized with CuSO 4 or 13(S)-HPODE (d, HDL ox ) was measured using monocytes from three (c) or at least four individual HIV À donors an in-vitro model of transendothelial migration and foam cell formation. Foam cell formation is expressed as % of total migrated cells (calculated as the median of n ¼ 12 technical replicates per donor), and the % foam cells averaged for all three (c) or at least four (d) donors for each HDL tested. Box and whisker plots show median, IQR, and 1.5 SDs (Tukey plot). All comparisons made using Mann-Whitney U-test; Ã P < 0.05, ÃÃ P < 0.01, ÃÃÃ P < 0.001.
as compared with monocytes incubated with unmodified HDL (P ¼ 0.004 and 0.0006 for CuSO 4 and 13(S)-HPODE HDL ox vs. unmodified HDL, respectively; Fig. 1d) . Indeed, the direct stimulation of foam cell formation with HDL ox generated with the more physiological reagent 13(S)-HPODE ( Fig. 1) was comparable with the effects of HIV(þ)HDL (Fig. 1c) .
Discussion
In this exploratory study, we found that HIV(þ)HDL from HIV þ individuals on effective ART had abnormal HDL function based on two independent cell-free assays and increased MDFCF in an established in-vitro model of atherogenesis. Notably, the selected HIV þ participants were all receiving a nucleoside reverse transcriptase inhibitors/nonnucleoside reverse transcriptase inhibitor regimen that is associated with a more favorable lipid profile compared with protease inhibitor-containing regimens, and had low overall CVD risk. Given our previous finding that monocytes isolated from HIV þ donors have heightened MDFCF potential [11] , it is possible that dysfunctional HDL from HIV þ persons may synergize with these proatherogenic monocytes, resulting in even more prominent effects on foam cell formation. We also showed that treatment of monocytes with HDL oxidized in vitro by two different mechanisms enhanced MDFCF. Given our prior data that dysfunctional HDL in chronic-treated HIV is oxidized, this suggests that oxidation underlies the atherogenic properties of HIV(þ)HDL. Our study is among the first that provides important mechanistic insight into the role of dysfunctional HDL as a possible driver of CVD in chronic-treated HIV infection. Our hypothesis is shown in Supplemental Figure 2 , http://links.lww.com/QAD/B159. Elucidating the mechanisms driving HDL-induced foam cells may identify oxidized HDL as a potential therapeutic target to reduce HIV-related CVD risk.
In-vitro studies indicate that oxidative modification of HDL may impair cholesterol efflux activity and inhibit HDL remodeling/exchange of apoA-I [8] , a CVDrelevant measure of HDL function [11] . We previously showed that dysfunctional HDL with impaired antioxidant HDL function (as measured by higher HDL ox ) in HIV þ individuals on long-term ART and without clinical CVD was associated with in-vivo progression of CVD [4] , may stimulate endothelial cells to induce monocyte/macrophage chemotaxis [3, 4] , was positively correlated with noncalcified coronary atherosclerotic plaque [5] , independently correlated with several markers of inflammation and immune activation [9] , and was associated with impaired HDL remodeling [8] . Here, we show that foam cell formation is enhanced when monocytes were exposed to chemically oxidized HDL, thus, linking HDL oxidation and impaired HDL function to processes which have a central role in HIV-related CVD.
The strengths of our study are the careful covariate phenotyping of our selected study population, including novel measures of HDL function and established physiologically relevant model of atherogenesis. Of note, MDFCF is not considered a function of HDL and, thus, the hypothesis that two abnormal HDL functions lead to a third impaired HDL function cannot explain our finding that dysfunctional HDL directly promotes MDFCF. However, all assays of HDL function have limitations [10] and HDL proteomics and cell-based cholesterol efflux assays were not performed. Other important limitations of our study include the small sample size and the inclusion of men only. Larger studies are needed to elucidate the differential effects of dysfunctional HDL on MDCF given the complex and unclear underlying physiological modulators of lipid metabolism responsible for the differences between men and women [12] . For our in-vitro assay, we used monocytes from HIV(À) donors only and, as mentioned above, it is possible that foam cell formation in response to HIV(þ) HDL might be further enhanced in monocytes from ART-treated and/or HIVinfected individuals. Here, we preselected HIV þ persons with evidence of dysfunctional HDL from a retrospective study, to specifically assess whether this dysfunction was associated with altered MDFCF. Such an approach is reasonable in the setting of a hypothesis-generating study, and we were able to demonstrate direct ex-vivo proatherogenic effects of dysfunctional HDL. These findings will inform larger studies to elucidate the mechanisms responsible for heightened MDFCF, and determine whether these effects may be more prominent in older HIV-1 infected persons and/or those with higher CVD risk.
In conclusion, our data provide important mechanistic insights into the role of dysfunctional HDL as possible driver of increased atherosclerotic risk in this population which warrants further investigation in larger prospective studies of subclinical atherosclerosis and CVD clinical events.
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